COLOMBO, BENEDETTA
 Distribuzione geografica
Continente #
AS - Asia 910
EU - Europa 59
NA - Nord America 46
OC - Oceania 3
Totale 1.018
Nazione #
SG - Singapore 882
US - Stati Uniti d'America 43
IT - Italia 33
CN - Cina 23
FI - Finlandia 12
GB - Regno Unito 5
CA - Canada 3
AU - Australia 2
DE - Germania 2
JP - Giappone 2
NL - Olanda 2
SE - Svezia 2
EE - Estonia 1
IN - India 1
IQ - Iraq 1
LT - Lituania 1
NZ - Nuova Zelanda 1
TR - Turchia 1
UA - Ucraina 1
Totale 1.018
Città #
Singapore 15
Ashburn 10
Boardman 9
Hefei 9
Helsinki 8
Shanghai 8
Los Angeles 6
Florence 5
Istrana 5
Rome 4
Seattle 4
Turku 4
Ciampino 3
Milan 3
Naples 3
Segrate 3
Bungarribee 2
Cardiff 2
Huizen 2
Lake Zurich 2
London 2
Occimiano 2
Auckland 1
Bologna 1
Borås 1
Boston 1
Brooklyn 1
Dalsjoefors 1
Fiesole 1
Manchester 1
Munich 1
Pittsburgh 1
Pune 1
San Francisco 1
Tokyo 1
Toronto 1
Vilnius 1
Zanica 1
Totale 127
Nome #
Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: A real-life perspective from the Italian chROnic migraiNe (IRON) project 162
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study 156
OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study 143
Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study 143
Phylogenetic Analysis of Multi-Drug Resistant Klebsiella pneumoniae Strains From Duodenoscope Biofilm: Microbiological Surveillance and Reprocessing Improvements for Infection Prevention 138
Advances on Human Immunodeficiency Virus Type 2 Infection 81
Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients 70
Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study 65
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study 61
Totale 1.019
Categoria #
all - tutte 3.382
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.382


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202220 0 0 0 0 0 0 0 0 0 0 0 20
2022/202313 0 0 0 1 4 0 2 1 3 0 2 0
2023/202432 0 3 1 10 2 7 0 6 2 0 0 1
2024/2025954 8 7 10 3 1 12 8 4 20 47 486 348
Totale 1.019